吡格列酮对A549肺癌细胞及RAW264.7巨噬细胞^(18)F-FDG摄取影响的实验研究

Experimental study of effect of pioglitazone on ^(18)F-FDG uptake in A549 lung cancer cells and RAW264.7 macrophages

目的探讨吡格列酮对A549肺癌细胞及RAW264.7巨噬细胞氟代脱氧葡萄糖(^(18)F-FDG)摄取的影响。方法用不同浓度(0、10、20、50、100、200μg/ml)的吡格列酮溶液分别作用于A549肺癌细胞及RAW264.7巨噬细胞1 h,加入^(18)F-FDG孵育0.5 h后,用γ计数仪分别检测细胞^(18)F-FDG摄取变化情况。用100μg/ml的吡格列酮作用细胞1 h,加入^(18)F-FDG分别孵育0.5、1.0、1.5、2.0、2.5、3.0 h,并以0μg/ml吡格列酮溶液作用细胞作为对照组,用γ计数仪分别检测以上6个时间点细胞^(18)F-FDG摄取变化情况,获得每分钟放射性计数(CMP)百分比。结果吡格列酮浓度为10、20、50、100、200μg/ml组A549肺癌细胞CMP百分比均高于0μg/ml组(P均<0.05)。吡格列酮浓度为10、20、50μg/ml组巨噬细胞CMP百分比与0μg/ml组比较差异均无统计学意义(P均> 0.05),吡格列酮浓度为100、200μg/ml组RAW264.7巨噬细胞的CMP百分比均低于0μg/ml组(P均<0.05)。在6个不同时间点,经吡格列酮作用后,肺癌细胞CMP百分比均高于对照组(P均<0.001),而巨噬细胞CMP百分比均低于对照组(P均<0.05)。结论较大剂量吡格列酮短期内能使A549肺癌细胞^(18)F-FDG摄取增高,而使RAW264.7巨噬细胞的^(18)F-FDG摄取减低。

Objective To evaluate the effect of pioglitazone on the 18F-fluorodeoxyglucose(^18F-FDG) uptake in the A549 lung cancer cells and RAW264.7 macrophages. Methods The A549 lung cancer cells and RAW264.7 macrophages were treated with different concentrations of pioglitazone solutions( 0, 10, 20, 50, 100 and 200 μg/ml) for 1 h. After incubation with ^18F-FDG for 0.5 h, the uptake of ^18F-FDG was detected by a γ counter. The cells were treated with 100 μg/ml pioglitazone for 1 h and incubated with ^18F-FDG for 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 h, respectively. The cells untreated with pioglitazone were assigned into the control group. The changes of the ^18F-FDG uptake at 6 time points were detected by a γ counter. The percentage of radioactive count per minute (CMP) was calculated. Results The percentage of CMP in the A549 lung cancer cells treated with 10, 20, 50, 100 and 200 μg/ml of pioglitazone was significantly higher than that in the cells without pioglitazone treatment (all P< 0.05). The percentage of CMP did not significantly differ between the RAW264.7 macrophages treated with 10, 20 and 50 μg/ml of pioglitazone and those untreated with pioglitazone (all P> 0.05). The percentage of CMP in the RAW264.7 macrophages treated with 100 and 200 μg/ml of pioglitazone was significantly lower than that in those without pioglitazone treatment( both P< 0.05). At 6 time points, the percentage of CMP in the lung cancer cells treated with pioglitazone was considerably higher than that in the control group (all P< 0.001), whereas the percentage of CMP in the macrophages treated with pioglitazone was significantly lower compared with that in the control group( all P< 0.05). Conclusion Treatment with a large dose of pioglitazone can increase the short-term ^18F-FDG uptake in the A549 lung cancer cells, whereas decrease the 18F-FDG uptake in the RAW264.7 macrophages.